Sage Therapeutics
$64.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$64.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$4.28 (+7.11%) Today
-$0.46 (-0.71%) As of 7:31 AM EST after-hours
Why Robinhood?
You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!
About SAGE
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Employees
637
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
3.12B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.86M
High Today
$65.83
Low Today
$61.02
Open Price
$62.86
Volume
5.59M
52 Week High
$193.56
52 Week Low
$56.50
Collections
SAGE News
BenzingaDec 6
Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment
Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analy
Analyst Ratings
84%
of 19 ratings
Buy
84%
Hold
11%
Sell
5%
SAGE Earnings
-$3.48
-$2.44
-$1.40
-$0.36
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Feb 18, Pre-Market